BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant

Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly acti...

詳細記述

書誌詳細

主要な著者:	Deepender Kaushik, Simran Dhingra, Madhuri T. Patil, Sakshi Piplani, Varun Khanna, Yoshikazu Honda-Okubo, Lei Li, Johnson Fung, Isaac G. Sakala, Deepak B. Salunke, Nikolai Petrovsky
フォーマット:	Artigo
言語:	Inglês
出版事項:	Taylor & Francis Group 2020-08-01
シリーズ:	Human Vaccines & Immunotherapeutics
主題:	imidazoquinoline tlr7 tlr8 imiquimod vaccine adjuvant influenza in-silico modeling
オンライン･アクセス:	http://dx.doi.org/10.1080/21645515.2019.1710409
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!